Antidepressant dosage taken by patients with bipolar disorder: Factors associated with irregularity

International Journal of Bipolar Disorders

Volumn 1, Issue 1, 2013, Pages 1-8

  Bauer, Rita ^a   Glenn, Tasha ^b   Alda, Martin ^c   Sagduyu, Kemal ^d   Marsh, Wendy ^e   Grof, Paul ^f,g   Munoz, Rodrigo ^h   Murray, Greg ⁱ   Ritter, Philipp ^a   Lewitzka, Ute ^a   Severus, Emanuel ^a   Whybrow, Peter C ^j   Bauer, Michael ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b ChronoRecord Association Inc   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g Mood Disorders Center of Ottawa   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; ESTROGEN; FLUOXETINE; MOOD STABILIZER; PAROXETINE; SERTRALINE; THYROID HORMONE; VENLAFAXINE;

ADULT; ARTICLE; BIPOLAR DISORDER; DEPRESSION; DRUG DOSE REGIMEN; EUPHORIA; EUTHYMIA; FEMALE; HUMAN; INFORMATION PROCESSING; LEISURE; MAJOR CLINICAL STUDY; MALE; MANIA; MOOD DISORDER; PRIORITY JOURNAL; VISUAL ANALOG SCALE;

EID: 85053396740     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/2194-7511-1-26     Document Type: Article

References (70)

1. Altshuler L, Suppes T, Black D, Nolen WA, Keck PE Jr, Frye MA, McElroy S, Kupka R, Grunze H, Walden J, Leverich G, Denicoff K, Luckenbaugh D, Post R. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry. 2003; 160:1252-1262.
2. Baldessarini RJ. Risks and implications of interrupting maintenance psychotropic drug therapy. Psychother Psychosom. 1995; 63:137-141.
3. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2006; 58:85-91.
4. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008a; 59:1175-1183.
5. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008; 23:95-105.
6. Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010; 167:934-941.
7. Bauer M, Grof P, Gyulai L, Rasgon N, Glenn T, Whybrow PC. Using technology to improve longitudinal studies: self-reporting with ChronoRecord in bipolar disorder. Bipolar Disord. 2004; 6:67-74.
8. Bauer M, Wilson T, Neuhaus K, Sasse J, Pfennig A, Lewitzka U, Grof P, Glenn T, Rasgon N, Bschor T, Whybrow PC. Self-reporting software for bipolar disorder: validation of ChronoRecord by patients with mania. Psychiatry Res. 2008; 159:359-366.
9. Bauer M, Glenn T, Keil M, Bauer R, Marsh W, Grof P, Alda M, Sagduyu K, Murray G, Quiroz D, Baethge C, Whybrow PC. Brief depressive symptoms in patients with bipolar disorder: analysis of long-term self-reported data. Aust N Z J Psychiatry. 2012; 46:1068-1078.
10. Bauer M, Glenn T, Alda M, Sagduyu K, Marsh W, Grof P, Munoz R, Severus E, Ritter P, Whybrow PC. Drug treatment patterns in bipolar disorder: analysis of long-term self-reported data. Int J Bipolar Disord. 2013; 1:5.
11. Bauer M, Glenn T, Alda M, Sagduyu K, Marsh W, Grof P, Munoz R, Baethge C, Lewitzka U, Pilhatsch M, Bauer R, Whybrow PC. Regularity in daily mood stabilizer dosage taken by patients with bipolar disorder. Pharmacopsychiatry. 2013; 46:163-168.
12. Belzeaux R, Correard N, Boyer L, Etain B, Loftus J, Bellivier F, Bougerol T, Courtet P, Gard S, Kahn JP, Passerieux C, Leboyer M, Henry C, Azorin JM, Fondamental Academic Centers of Expertise for Bipolar Disorders (FACE-BD) collaborators. Depressive residual symptoms are associated with lower adherence to medication in bipolar patients without substance use disorder: results from the FACE-BD cohort. J Affect Disord. 2013; 151:1009-1015.
13. Berk L, Hallam KT, Colom F, Vieta E, Hasty M, Macneil C, Berk M. Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol. 2010; 25:1-16.
14. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008; 28:437-443.
15. Bulloch AG, Patten SB. Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol. 2010; 45:47-56.
16. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23:1296-1310.
17. Colom F, Vieta E, Martínez-Arán A, Reinares M, Benabarre A, Gastó C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 2000; 61:549-555.
18. Comté L, Vrijens B, Tousset E, Gérard P, Urquhart J. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn. 2007; 34:549-558.
19. Conrad P. The meaning of medications: another look at compliance. Soc Sci Med. 1985; 20:29-37.
20. Cooper C, Bebbington P, King M, Brugha T, Meltzer H, Bhugra D, Jenkins R. Whypeople do not take their psychotropic drugs as prescribed: results of the 2000 National Psychiatric Morbidity Survey. Acta Psychiatr Scand. 2007; 116:47-1153.
21. Dell'Osso L, Pini S, Cassano GB, Mastrocinque C, Seckinger RA, Saettoni M, Papasogli A, Yale SA, Amador XF. Insight into illness in patients with mania, mixed mania, bipolar depression and major depression with psychotic features. Bipolar Disord. 2002; 4:315-322.
22. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160:2101-2107.
23. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry. 2000; 48:593-604.
24. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004; 42:649-652.
25. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand. 2008; 118:347-356.
26. Goldberg JF, Brooks JO 3rd, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, Miklowitz DJ, Ketter TA, Sachs GS, Thase ME. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009; 70:155-162.
27. Greil W, Häberle A, Haueis P, Grohmann R, Russmann S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord. 2012; 136:534-542.
28. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001; 24:183-197.
29. Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry. 2012; 12:153.
30. Harter JG, Peck CC. Chronobiology. Suggestions for integrating it into drug development. Ann N Y Acad Sci. 1991; 618:563-571.
31. Hayes J, Prah P, Nazareth I, King M, Walters K, Petersen I, Osborn D. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS One. 2011; 6:e28725.
32. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008: CD000011. doi:10.1002/14651858.CD000011.pub3.
33. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008; 31:213-224.
34. Johnson FR, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med Care. 2007; 45:545-552.
35. Jónsdóttir H, Opjordsmoen S, Birkenaes AB, Engh JA, Ringen PA, Vaskinn A, Aamo TO, Friis S, Andreassen OA. Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol. 2010; 30:169-175.
36. Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol. 2002; 17:217-225.
37. Keck PE Jr, McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balistreri TM, Bennett JA, Tugrul KC, West SA. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry. 1996; 57:292-297.
38. Keck PE Jr, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, Bourne ML, Haggard P. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry. 1998; 155:646-652.
39. Kilbourne AM, Cornelius JR, Han X, Pincus HA, Shad M, Salloum I, Conigliaro J, Haas GL. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004; 6:368-373.
40. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005; 67:1-8.
41. Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, Parr-Davis G, Sham P. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry. 2003; 60:145-152.
42. Lavantes B, Senimon F, Bayle FJ. Compliance with and tolerance of sustained-release lithium carbonate. Encéphale. 1999; 25:152-157.
43. Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord. 2013; 149:247-252.
44. Libby AM, Fish DN, Hosokawa PW, Linnebur SA, Metz KR, Nair KV, Saseen JJ, Vande Griend JP, Vu SP, Hirsch JD. Patient-level medication regimen complexity across populations with chronic disease. Clin Ther. 2013; 35:385-398.
45. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002; 105:164-172.
46. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010; 67:26-36.
47. Möller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci. 2000; 250:57-68.
48. Osterberg LG, Urquhart J, Blaschke TF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010; 88:457-459.
49. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Ghaemi SN, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, Gonzalez-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, et al. The International Society for Bipolar Disorders (ISBD) Task Force Report on anti-depressant use in bipolar disorders. Am J Psychiatry. 2013; 170:1249-1262.
50. Pan W, Connett JE. Selecting the working correlation structure in generalized estimating equations with application to the lung health study. Statistica Sinica. 2002; 12:475-490.
51. Patel NC, Crismon ML, Miller AL, Johnsrud MT. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy. 2005; 25:1242-1247.
52. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004; 94:1782-1787.
53. Pincus SM, Gladstone IM, Ehrenkranz RA. A regularity statistic for medical data analysis. J Clin Monit. 1991; 7:335-345.
54. Pincus SM, Hartman ML, Roelfsema F, Thorner MO, Veldhuis JD. Hormone pulsatility discrimination via coarse and short time sampling. Am J Physiol. 1999; 277:E948-E957.
55. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, Campbell R. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med. 2005; 61:133-155.
56. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008; 300:2867-2878
57. Quante A, Zeugmann S, Regen F, Engelhardt A, Anghelescu IG. Psychopharmacological treatment status in outpatients with bipolar disorder: a clinical survey in Germany. Psychiatry Investig. 2010; 7:155-162
58. Richter A, Anton SE, Koch P, Dennett SL The impact of reducing dose frequency on health outcomes. Clin Ther. 2003; 25:2307-2335
59. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998; 44:77-87
60. Ryan GW, Wagner GJ. Pill taking 'routinization': a critical factor to understanding episodic medication adherence. AIDS Care. 2003; 15:795-806.
61. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009; 15:e22-e33.
62. Sajatovic M, Ignacio RV, West JA, Cassidy KA, Safavi R, Kilbourne AM, Blow FC. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. Compr Psychiatry. 2009; 50:100-107.
63. Sajatovic M, Velligan DI, Weiden PJ, Valenstein MA, Ogedegbe G. Measurement of psychiatric treatment adherence. J Psychosom Res. 2010; 69:591-599
64. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics. 2010; 28:1097-1107.
65. Sussman M, Friedman M, Korn JR, Hassan M, Kim J, Menzin J. The relationship between use of antidepressants and resource utilization among patients with manic or mixed bipolar disorder episodes: findings from a managed care setting. J Affect Disord. 2012; 138:425-432.
66. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J. 1996; 17(Suppl A):8-15.
67. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet. 1997; 32:345-356
68. Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev. 1998; 33:207-219
69. Vrijens B, Gross R, Urquhart J. The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses. Basic Clin Pharmacol Toxicol. 2005; 96:225-227
70. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009; 47:826-834